Serum amyloid protein A concentration in cryopyrin-associated periodic syndrome patients treated with interleukin-1 beta antagonist

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S63-S66

  Pastore, Serena ^a,b   Paloni, Giulia ^a,b   Caorsi, Roberta ^c   Ronfani, Luca ^b   Taddio, Andrea ^a,b   Lepore, L ^b   Alessio, Maria ^d   Cantarini, Luca ^e   Cattalini, Marco ^f   Consolini, Rita ^g   Gattorno, Marco ^c   Gerloni, Valeria ^h   Insalaco, Antonella ⁱ   Martini, Giorgia ^j   Martino, Silvana ^k   Obici, Laura ^l   Rigante, Donato ^m  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h Department of Rheumatology   (Italy)

ⁱ BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^j UNIVERSITY OF PADOVA   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

^l FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^m CATHOLIC UNIVERSITY   (Italy)

more..

Author keywords

Amyloidosis; Cryopyrin associated periodic syndromes; IL 1 inhibitor; Inflammation; Serum amyloid protein A

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; CANAKINUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1BETA; SERUM AMYLOID A;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; CHILD; CINCA SYNDROME; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MALE; PROTEIN BLOOD LEVEL; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; AMYLOIDOSIS; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DRUG MONITORING; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AMYLOIDOSIS; CHILD; CHILD, PRESCHOOL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; DRUG MONITORING; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; SERUM AMYLOID A PROTEIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907509450     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. TOUITOU I, KONé-PAUT I: Autoinflammatory diseases. Best Pract Res Clin Rheumatol 2008; 22: 811-29.
2. LACHMANN HJ: Clinical immunology review series: An approach to the patient with a periodic fever syndrome. Clin Exp Immunol 2011; 165: 301-9.
3. AKSENTIJEVICH I, D PUTNAM C, REMMERS EF et al.: The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007; 56: 1273-85.
4. OMENETTI A, FEDERICI S, GATTORNO M: Inherited autoinflammatory diseases: a critical digest of the recent literature. Clin Exp Rheumatol 2013; 31: 118-26.
5. LACHMANN HJ, KONE-PAUT I, KUEMMERLE-DESCHNER JB et al.: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
6. KUEMMERLE-DESCHNER JB, HACHULLA E, CARTWRIGHT R et al.: Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011; 70: 2095-102.
7. IMAGAWA T, NISHIKOMORI R, TAKADA H et al.: Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol 2013; 31: 302-9.
8. LEPORE L, PALONI G, CAORSI R et al.: Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr 2010; 157: 310-5.
9. Van der HILST JCH: Recent insights into the pathogenesis of type AA amyloidosis. Scientific World Journal 2011; 11: 641-50.
10. LEDUE TB, WEINER DL, SIPE JD et al.: Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 1998; 35: 745-53.
11. LAIHO K, TIITINEN S, KAARELA K, HELIN H, ISOMäKI H: Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol 1999; 18: 122-3.
12. SINGH G, KUMARI N, AGGARWAL A, KRISHNANI N, MISRA R: Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 2007; 34: 371-3.
13. LACHMANN HJ, QUARTIER P, SO A, HAWKINS PN: The emerging role of interleukin-1ß in autoinflammatory diseases. Arthritis Rheum 2011; 63: 314-24.
14. BILGINER Y, AKPOLAT T, OZEN S: Renal amyloidosis in children. Pediatr Nephrol 2011; 26: 1215-27.
15. GERSHONI-BARUCH R, BRIK R, ZACKS N, SHINAWI M, LIDAR M, LIVNEH A: The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum 2003; 48: 1149-55.
16. SHOHAT M, MAGAL N, SHOHAT T et al.: Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet 1999; 7: 287-92.
17. INSALACO A, PRENCIPE G, BUONUOMO PS et al.: A novel mutation in the CIAS1/NLRP3 gene associated with an unexpected phenotype of CAPS. Clin Exp Rheumatol 2014; 32: 123-5.
18. OBICI L, MERLINI G: Amyloidosis in autoinflammatory syndromes. Autoimmun Rev 2012; 12: 14-7.